Home » Stocks » Kodiak Sciences

Kodiak Sciences Inc. (KOD)

Stock Price: $97.74 USD 1.08 (1.12%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.37B
Revenue (ttm) n/a
Net Income (ttm) -78.39M
Shares Out 44.71M
EPS (ttm) -1.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $97.74
Previous Close $96.66
Change ($) 1.08
Change (%) 1.12%
Day's Open 96.95
Day's Range 94.84 - 102.74
Day's Volume 463,152
52-Week Range 18.52 - 102.74

More Stats

Market Cap 4.37B
Enterprise Value 3.95B
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.71M
Float 37.51M
EPS (basic) -1.85
EPS (diluted) -1.88
FCF / Share -1.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.71M
Short Ratio 12.34
Short % of Float 9.88%
Beta 1.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 13.97
Revenue n/a
Operating Income -81.42M
Net Income -78.39M
Free Cash Flow -51.39M
Net Cash 415.55M
Net Cash / Share 9.29
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -20.05%
ROE -41.34%
ROIC -61.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 7
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(-16.62% downside)
Current: $97.74
Target: 81.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-49.19-26.37-25.52-17.15
Net Income-47.37-41.44-27.94-17.13
Shares Outstanding37.8514.987.527.21
Earnings Per Share-1.25-2.77-3.72-2.38
Operating Cash Flow-39.15-29.03-17.66-16.05
Capital Expenditures-0.44-0.58-0.21-0.77
Free Cash Flow-39.58-29.61-17.86-16.82
Cash & Equivalents33788.391.549.76
Total Debt1.94-9.920.10
Net Cash / Debt33588.39-8.399.66
Book Value34586.83-68.74-41.08
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kodiak Sciences Inc.
Country United States
Employees 48
CEO Victor Perlroth

Stock Information

Ticker Symbol KOD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KOD
IPO Date October 4, 2018


Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.